Wide Ranks

LIXT

Lixte Biotechnology Holdings, I

2.17

Top Statistics
Market Cap 4 M Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 6.33 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 2 M Total Cash Per Share 1.15 Total Debt
Total Debt To Equity Current Ratio 6.33 Book Value Per Share 0.2200
All Measures
Short Ratio 31.00 % Message Board Id finmb_29181356 Fax 631 982 5050
Shares Short Prior Month 24929 Return On Equity -1.63 City Pasadena
Uuid a941de37-b47d-353c-8260-973e88a724c1 Previous Close 2.06 First Trade Date Epoch Utc 1 B
Book Value 0.2200 Beta -0.1720 Volume 12743
Price To Book 9.86 Last Split Date 1 B Fifty Two Week Low 1.31
Total Cash Per Share 1.15 Shares Short Previous Month Date 1 B Max Age 86400
Sand P52 Week Change 0.3133 Net Income To Common -4033256 Short Percent Of Float 0.2044
Implied Shares Outstanding 2 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 29720 Average Volume10days 29720 Total Cash 2 M
Next Fiscal Year End 1 B Held Percent Insiders 0.2047 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 2.06
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.81
Open 2.04 Free Cashflow -1951453 State CA
Dividend Yield 0.00 % Return On Assets -0.8733 Time Zone Short Name EST
Trailing Eps -1.73 Day Low 2.04 Address1 680 East Colorado Boulevard
Shares Outstanding 2 M Price Hint 4 Target High Price 0.0000
Website https://lixte.com 52 Week Change -0.0687 Average Volume 587409
Recommendation Key none Forward Eps 0.0000 Compensation As Of Epoch Date 1 B
Quick Ratio 615.80 % Last Split Factor 1:10 Regular Market Day High 2.21
Is_sp_500 False Profit Margins 0.00 % Fifty Two Week High 4.40
Day High 2.21 Shares Short 447991 Regular Market Open 2.04
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.1992 Operating Cashflow -3454778 Currency USD
Time Zone Full Name America/New_York Market Cap 4 M Is_nasdaq_100 False
Zip 91101 Quote Type EQUITY Industry Biotechnology
Long Name Lixte Biotechnology Holdings, Inc. Regular Market Day Low 2.04 Held Percent Institutions 0.0964
Current Price 2.17 Address2 Suite 180 Financial Currency USD
Current Ratio 6.33 Industry Disp Biotechnology Country United States
Float Shares 1 M Two Hundred Day Average 2.31 Enterprise Value 4 M
Forward PE 0.0000 Regular Market Volume 12743 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.

Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.

The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.

The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute.

Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.